U.S. markets closed
  • S&P 500

    +40.81 (+0.80%)
  • Dow 30

    +90.99 (+0.23%)
  • Nasdaq

    +183.02 (+1.14%)
  • Russell 2000

    +21.55 (+1.05%)
  • Crude Oil

    +1.55 (+1.98%)
  • Gold

    +36.90 (+1.80%)
  • Silver

    +0.46 (+2.01%)

    +0.0032 (+0.29%)
  • 10-Yr Bond

    -0.0720 (-1.69%)

    +0.0029 (+0.23%)

    +0.0800 (+0.05%)
  • Bitcoin USD

    -298.03 (-0.48%)
  • CMC Crypto 200

    0.00 (0.00%)
  • FTSE 100

    +52.48 (+0.69%)
  • Nikkei 225

    +744.63 (+1.90%)

Insider Sell Alert: Chief Med. & Reg. ...

In a notable insider transaction, Gary Ingenito, the Chief Medical and Regulatory Officer of Catalyst Pharmaceuticals Inc, has sold 50,000 shares of the company on December 6, 2023. This move has caught the attention of investors and market analysts, as insider transactions can often provide valuable insights into a company's prospects.

Who is Gary Ingenito?

Gary Ingenito plays a crucial role at Catalyst Pharmaceuticals Inc as the Chief Medical and Regulatory Officer. His responsibilities include overseeing the development of the company's drug candidates and ensuring they meet regulatory standards. Ingenito's background in medicine and regulatory affairs provides him with the expertise necessary to navigate the complex landscape of drug approval processes. His actions, particularly in selling or buying company stock, are closely watched as they may reflect his confidence in the company's future.

About Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. The company has a portfolio of products designed to address the unmet medical needs of patients with these conditions. Catalyst Pharmaceuticals' commitment to improving the lives of those affected by rare diseases is at the core of its business strategy.

Analysis of Insider Buy/Sell and Relationship with Stock Price

The insider transaction history for Catalyst Pharmaceuticals Inc reveals a pattern of insider selling over the past year. Gary Ingenito's recent sale of 50,000 shares is part of a broader trend, with no insider buys recorded and a total of 7 insider sells during the same timeframe. This could signal a lack of confidence among insiders about the company's short-term growth prospects or simply reflect personal financial planning decisions by the insiders.When analyzing the impact of insider transactions on stock prices, it is essential to consider the context and volume of the trades. While a single insider selling shares does not necessarily indicate a problem within the company, a pattern of selling by multiple insiders could be a red flag for investors. However, it is also important to note that insiders may sell shares for various reasons unrelated to the company's performance, such as diversifying their investment portfolio or meeting personal financial obligations.

Insider Sell Alert: Chief Med. & Reg. Officer Gary Ingenito Sells 50,000 Shares of Catalyst Pharmaceuticals Inc (CPRX)
Insider Sell Alert: Chief Med. & Reg. Officer Gary Ingenito Sells 50,000 Shares of Catalyst Pharmaceuticals Inc (CPRX)

Insider Trends

The insider trend image above provides a visual representation of the buying and selling activities of insiders at Catalyst Pharmaceuticals Inc. The absence of insider buys over the past year, coupled with consistent selling, may lead some investors to question the long-term value of the stock. However, it is crucial to analyze these trends in conjunction with other financial metrics and company developments.

Valuation and Market Cap

On the day of Gary Ingenito's recent sale, shares of Catalyst Pharmaceuticals Inc were trading at $14.02, giving the company a market cap of $1.508 billion. The price-earnings ratio of 27.21 is lower than the industry median of 31.28 but higher than the company's historical median price-earnings ratio. This suggests that the stock is trading at a more attractive valuation compared to its peers but may be slightly overvalued based on its own historical standards.With a current price of $14.02 and a GuruFocus Value of $17.22, Catalyst Pharmaceuticals Inc has a price-to-GF-Value ratio of 0.81, indicating that the stock is modestly undervalued based on its GF Value.

Insider Sell Alert: Chief Med. & Reg. Officer Gary Ingenito Sells 50,000 Shares of Catalyst Pharmaceuticals Inc (CPRX)
Insider Sell Alert: Chief Med. & Reg. Officer Gary Ingenito Sells 50,000 Shares of Catalyst Pharmaceuticals Inc (CPRX)

The GF Value is a proprietary intrinsic value estimate developed by GuruFocus, which takes into account historical trading multiples, a GuruFocus adjustment factor based on past returns and growth, and future business performance estimates from Morningstar analysts. The modest undervaluation of Catalyst Pharmaceuticals Inc suggests that the stock may have room for appreciation, despite the recent insider selling activity.


The sale of 50,000 shares by Chief Medical and Regulatory Officer Gary Ingenito is a significant event for Catalyst Pharmaceuticals Inc and its investors. While the insider selling trend over the past year may raise questions, it is essential to consider the broader financial context and valuation metrics. The stock's modest undervaluation according to the GF Value, combined with its competitive price-earnings ratio, suggests that Catalyst Pharmaceuticals Inc may still offer investment value. Investors should continue to monitor insider activity and company developments to make informed decisions.

This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.

This article first appeared on GuruFocus.